-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Male hypogonadism is associated with low bone density and increased risk of fragility fractures.
diabetes
Recently, a research article was published in the Journal of Clinical Endocrinology & Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, which aims to evaluate hypogonadal men with type 2 diabetes compared with hypogonadal men without T2D The effect of testosterone treatment on the skeletal system.
This single-group, open-label clinical (NCT01378299) trial included 105 men (40-74 years old) with early morning testosterone levels <300ng/dl.
In the hypogonadal male population, 49 subjects had T2D, while 56 subjects did not have T2D.
It can be seen that testosterone therapy can improve the bone condition of male patients with hypogonadism with T2D better than male patients without T2D.
Testosterone therapy can improve the bone condition of male patients with hypogonadism with T2D better than that of male patients without T2D.
Original source:
Georgia Colleluori.
org/10.
1210/clinem/dgab181" target="_blank" rel="noopener">Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes in this message